Moreover, the addition of TGF-β could not reverse TUG1-knockout-induced inhibition of migration and invasion, suggesting that TUG1 is a downstream component of TGF-β signaling, and might be a potential therapeutic target against CRC metastasis. Here, TUG1 is linked to colorectal carcinoma.